@article{JTD14490,
author = {Céline Dreyfuss-Tubiana and Philippe Sosner and Jacques Blacher},
title = {Target blood pressure and cardiovascular risk},
journal = {Journal of Thoracic Disease},
volume = {9},
number = {7},
year = {2017},
keywords = {},
abstract = {An article recently published in the Lancet (1) concerned a meta-analysis of two therapeutic trials ONTARGET (2) and TRANSCEND (3). They were both designed to compare angiotensin receptor blocker (ARB) to angiotensin-converting enzyme (ACE) inhibitors (or their combination) or placebo respectively, to reduce the rate of a composite of cardiovascular death, myocardial infarction (MI), stroke and hospital admission for heart failure, among patients at high risk for cardiovascular events.},
issn = {2077-6624}, url = {https://jtd.amegroups.org/article/view/14490}
}